Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Geode Capital Management LLC

Geode Capital Management LLC lowered its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 1.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,236,312 shares of the biopharmaceutical company's stock after selling 34,895 shares during the quarter. Geode Capital Management LLC owned approximately 2.06% of Ocular Therapeutix worth $27,644,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. Artisan Partners Limited Partnership increased its holdings in shares of Ocular Therapeutix by 26.4% in the fourth quarter. Artisan Partners Limited Partnership now owns 1,334,702 shares of the biopharmaceutical company's stock valued at $11,398,000 after purchasing an additional 278,610 shares during the period. Rosalind Advisors Inc. increased its stake in Ocular Therapeutix by 27.5% in the 4th quarter. Rosalind Advisors Inc. now owns 1,128,700 shares of the biopharmaceutical company's stock valued at $9,639,000 after buying an additional 243,700 shares during the period. Raymond James Financial Inc. purchased a new position in Ocular Therapeutix during the 4th quarter worth $1,722,000. RoundAngle Advisors LLC purchased a new position in Ocular Therapeutix during the 4th quarter worth $1,695,000. Finally, Barclays PLC lifted its stake in shares of Ocular Therapeutix by 37.1% in the 3rd quarter. Barclays PLC now owns 511,522 shares of the biopharmaceutical company's stock worth $4,451,000 after acquiring an additional 138,441 shares during the period. 59.21% of the stock is owned by institutional investors and hedge funds.

Ocular Therapeutix Price Performance

Ocular Therapeutix stock traded up $0.22 during trading hours on Wednesday, hitting $8.13. The stock had a trading volume of 182,727 shares, compared to its average volume of 1,510,462. Ocular Therapeutix, Inc. has a 1-year low of $4.06 and a 1-year high of $11.78. The stock has a market capitalization of $1.29 billion, a price-to-earnings ratio of -6.16 and a beta of 1.49. The stock's fifty day moving average is $7.23 and its two-hundred day moving average is $8.50. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. The business had revenue of $17.08 million for the quarter, compared to analysts' expectations of $16.89 million. As a group, analysts predict that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on OCUL. Royal Bank of Canada began coverage on shares of Ocular Therapeutix in a research note on Tuesday, March 18th. They set an "outperform" rating and a $17.00 price target on the stock. HC Wainwright reissued a "buy" rating and set a $15.00 target price on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. JMP Securities set a $19.00 price target on Ocular Therapeutix in a report on Tuesday, March 4th. William Blair began coverage on Ocular Therapeutix in a report on Tuesday, April 8th. They set an "outperform" rating on the stock. Finally, Needham & Company LLC reissued a "buy" rating and issued a $15.00 target price on shares of Ocular Therapeutix in a report on Tuesday, April 8th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $16.38.

Insider Buying and Selling

In other news, insider Pravin Dugel sold 21,475 shares of the firm's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $6.87, for a total transaction of $147,533.25. Following the sale, the insider now owns 3,520,318 shares in the company, valued at $24,184,584.66. This trade represents a 0.61 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Donald Notman sold 11,119 shares of Ocular Therapeutix stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $7.81, for a total value of $86,839.39. Following the completion of the sale, the insider now directly owns 193,444 shares of the company's stock, valued at approximately $1,510,797.64. This represents a 5.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,895 shares of company stock worth $283,772 in the last ninety days. Insiders own 3.50% of the company's stock.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.